Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bespoke ExtractsBSPK +28.57% EV-to-EBITDA is -2.52 as of Jul. 27, 2026. The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Bespoke Extracts ranks worse than 134770.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bespoke Extracts's enterprise value is $1.42 Mil.
Bespoke Extracts's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.57 Mil. Therefore, Bespoke Extracts's EV-to-EBITDA for today is -2.52.
The historical rank and industry rank for Bespoke Extracts's EV-to-EBITDA or its related term are showing as below:
BSPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.2 Med: -1.78 Max: 3.26
Current: -2.52
During the past 13 years, the highest EV-to-EBITDA of Bespoke Extracts was 3.26. The lowest was -13.20. And the median was -1.78.
BSPK's EV-to-EBITDA is ranked worse than 100% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs BSPK: -2.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bespoke Extracts's PE Ratio (TTM) for today is calculated as:
Bespoke Extracts's share price for today is $0.0009.
Bespoke Extracts's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bespoke Extracts's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bespoke Extracts's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bespoke Extracts EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bespoke Extracts's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bespoke Extracts's EV-to-EBITDA falls into.
Bespoke Extracts's current Enterprise Value is $1.42 Mil.
Bespoke Extracts's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bespoke Extracts (BSPK) has a EV-to-EBITDA of -2.52 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bespoke Extracts. According to the industry distribution chart, Bespoke Extracts ranks #999999 out of 742 companies in the Drug Manufacturers industry.
Is Bespoke Extracts' EV-to-EBITDA too high?
Bespoke Extracts' current EV-to-EBITDA is -2.52. Based on the distribution chart, Bespoke Extracts ranks #999999 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Bespoke Extracts' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bespoke Extracts ranks #999999 out of 742 companies for EV-to-EBITDA. This places Bespoke Extracts in the lower half of its industry. The industry median EV-to-EBITDA is 12.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bespoke Extracts. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bespoke Extracts's current EV-to-EBITDA is -2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bespoke Extracts stock overvalued right now?
Bespoke Extracts (BSPK) has a current EV-to-EBITDA of -2.52. The current EV-to-EBITDA is -2.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bespoke Extracts (BSPK), the current EV-to-EBITDA is -2.52 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, quality, hemp-derived CBD products. The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSPK has been successfully added to your 
